Compare IPCA Labs with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs WOCKHARDT - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS WOCKHARDT IPCA LABS/
WOCKHARDT
 
P/E (TTM) x 22.8 -23.0 - View Chart
P/BV x 4.4 1.2 364.7% View Chart
Dividend Yield % 0.1 0.0 3,336.3%  

Financials

 IPCA LABS   WOCKHARDT
EQUITY SHARE DATA
    IPCA LABS
Mar-18
WOCKHARDT
Mar-18
IPCA LABS/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs6951,012 68.7%   
Low Rs400532 75.3%   
Sales per share (Unadj.) Rs260.2355.9 73.1%  
Earnings per share (Unadj.) Rs19.0-60.3 -31.5%  
Cash flow per share (Unadj.) Rs33.1-46.8 -70.7%  
Dividends per share (Unadj.) Rs1.000.01 10,000.0%  
Dividend yield (eoy) %0.20 14,090.7%  
Book value per share (Unadj.) Rs213.0257.8 82.6%  
Shares outstanding (eoy) m126.20110.63 114.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.12.2 97.1%   
Avg P/E ratio x28.9-12.8 -225.5%  
P/CF ratio (eoy) x16.6-16.5 -100.4%  
Price / Book Value ratio x2.63.0 85.9%  
Dividend payout %5.30 -31,772.7%   
Avg Mkt Cap Rs m69,12085,379 81.0%   
No. of employees `00013.36.3 211.9%   
Total wages/salary Rs m7,3599,371 78.5%   
Avg. sales/employee Rs Th2,477.46,295.0 39.4%   
Avg. wages/employee Rs Th555.21,498.3 37.1%   
Avg. net profit/employee Rs Th180.6-1,066.3 -16.9%   
INCOME DATA
Net Sales Rs m32,83639,369 83.4%  
Other income Rs m4181,202 34.8%   
Total revenues Rs m33,25440,571 82.0%   
Gross profit Rs m4,50518 24,616.4%  
Depreciation Rs m1,7771,495 118.9%   
Interest Rs m2402,555 9.4%   
Profit before tax Rs m2,905-2,830 -102.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m511257 198.9%   
Profit after tax Rs m2,394-6,669 -35.9%  
Gross profit margin %13.70 29,514.3%  
Effective tax rate %17.6-9.1 -193.7%   
Net profit margin %7.3-16.9 -43.0%  
BALANCE SHEET DATA
Current assets Rs m19,45533,796 57.6%   
Current liabilities Rs m10,07626,917 37.4%   
Net working cap to sales %28.617.5 163.5%  
Current ratio x1.91.3 153.8%  
Inventory Days Days9879 123.4%  
Debtors Days Days6789 75.0%  
Net fixed assets Rs m20,26039,664 51.1%   
Share capital Rs m252553 45.6%   
"Free" reserves Rs m26,63327,968 95.2%   
Net worth Rs m26,88628,522 94.3%   
Long term debt Rs m2,34021,731 10.8%   
Total assets Rs m41,17381,620 50.4%  
Interest coverage x13.1-0.1 -12,179.6%   
Debt to equity ratio x0.10.8 11.4%  
Sales to assets ratio x0.80.5 165.3%   
Return on assets %6.4-5.0 -127.0%  
Return on equity %8.9-23.4 -38.1%  
Return on capital %10.8-7.7 -140.2%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6429,807 159.5%   
Fx outflow Rs m4,8841,789 273.0%   
Net fx Rs m10,7598,019 134.2%   
CASH FLOW
From Operations Rs m3,411684 498.4%  
From Investments Rs m-1,3546,302 -21.5%  
From Financial Activity Rs m-1,304-7,695 16.9%  
Net Cashflow Rs m753-664 -113.4%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 2.3 495.7%  
FIIs % 25.3 7.7 328.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.4 15.4 113.0%  
Shareholders   36,892 67,757 54.4%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 13, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS